-

PharmaEssentia to Present at the 39th Virtual Annual J.P. Morgan Healthcare Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced its plans to present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. Meredith Manning, PharmaEssentia’s U.S. General Manager, is scheduled to present on Monday, January 11, 2021 at 10:25 a.m. Eastern Time.

About PharmaEssentia

PharmaEssentia Corporation (TPEx: 6446) is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product already approved in Europe and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today the company is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung.

Contacts

PharmaEssentia Corporation

TW:6446

Release Summary
PharmaEssentia's U.S. General Manager, Meredith Manning, will present at the J.P. Morgan Healthcare Conference on January 11 at 10:25 am ET.
Release Versions

Contacts

More News From PharmaEssentia Corporation

PharmaEssentia Establishes a New Research and Development Facility in the Boston Area

TAIPEI,Taiwan--(BUSINESS WIRE)--PharmaEssentia today announced plans for a new PharmaEssentia Innovation Research Center (PIRC) in the greater Boston, Massachusetts area....

PharmaEssentia to Present at the 41st Annual J.P. Morgan Healthcare Conference

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023....

New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia today announced new data on ropeginterferon alfa-2b-njft is presented at the ASH Annual Meeting....
Back to Newsroom